Ameritas Investment Partners buys $8,267,069 stake in Amgen (AMGN)

Amgen (AMGN) : Ameritas Investment Partners scooped up 1,138 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 47,781 shares of Amgen which is valued at $8,267,069.Amgen makes up approximately 0.53% of Ameritas Investment Partners’s portfolio.

Other Hedge Funds, Including , Frontier Wealth Management boosted its stake in AMGN in the latest quarter, The investment management firm added 19 additional shares and now holds a total of 53,483 shares of Amgen which is valued at $9,253,629. Amgen makes up approx 1.31% of Frontier Wealth Management’s portfolio.Geneva Advisors reduced its stake in AMGN by selling 851 shares or 10.03% in the most recent quarter. The Hedge Fund company now holds 7,634 shares of AMGN which is valued at $1,316,331. Amgen makes up approx 0.03% of Geneva Advisors’s portfolio.Blue Fin Capital reduced its stake in AMGN by selling 5 shares or 0.11% in the most recent quarter. The Hedge Fund company now holds 4,693 shares of AMGN which is valued at $807,337. Amgen makes up approx 0.65% of Blue Fin Capital’s portfolio.Benedict Financial Advisors Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 1,113 additional shares and now holds a total of 19,058 shares of Amgen which is valued at $3,252,819. Amgen makes up approx 1.88% of Benedict Financial Advisors Inc’s portfolio.Baring Asset Management Ltd reduced its stake in AMGN by selling 451 shares or 0.89% in the most recent quarter. The Hedge Fund company now holds 49,992 shares of AMGN which is valued at $8,532,635. Amgen makes up approx 0.67% of Baring Asset Management Ltd’s portfolio.

Amgen closed down -1.13 points or -0.65% at $173.62 with 26,96,372 shares getting traded on Friday. Post opening the session at $174.1, the shares hit an intraday low of $172.26 and an intraday high of $174.96 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.